Delving into the Latest Updates on Antares Therapeutics, Inc. with Synapse

概览

关联

1

项与 Antares Therapeutics, Inc. 相关的临床试验

NCT06043817

/ Recruiting临床1/2期

First-In-Human Study of STX-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

Study STX-721-101 is an open label, Phase 1/2 study evaluating the safety, tolerability, pharmacokinetic (PK) exposure, and preliminary antitumor activity of STX-721 in participants with non-small cell lung cancer (NSCLC) carrying EGFR/HER2 exon 20 insertion (ex20ins) mutations.

开始日期2023-09-26

申办/合作机构

Antares Therapeutics, Inc.

100 项与 Antares Therapeutics, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Antares Therapeutics, Inc. 相关的专利（医药）

登录后查看更多信息

100 项与 Antares Therapeutics, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Antares Therapeutics, Inc. 相关的转化医学

登录后查看更多信息